FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan

FDA News, New FDA Approvals
December 17, 2020
A+ A-
Email Print

Article Link: FDA Approves Riabni (rituximab-arrx), a Biosimilar to Rituxan

THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Riabni (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult…

Source: FDA New Drug Approvals

Newer Post
Older Post